Renal cell carcinoma (RCC)
Cancer of the kidney; target indication for everolimus treatment in clinical practice.
A kidney cancer treated with these drugs.
Temsirolimus (ARCC) and everolimus (RECORD-1) both improved outcomes; exceptional responders have been traced to TSC1 loss.
Evidence at a glance
| Evidence | What it means | Studies |
|---|---|---|
| H | Human study | 2 |
| R | Review — secondary literature, not a new result | 1 |
Studies
| Year | Evidence | Study |
|---|---|---|
| 2008 | H | Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial MOT2008 Everolimus extended median progression-free survival from 1.9 to 4.0 months versus placebo in metastatic renal cell carcinoma. |
| 2007 | H | Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma HUD2007 Temsirolimus alone extended median overall survival to 10.9 months versus 7.3 months with interferon alfa in poor-prognosis metastatic kidney cancer; rash, hyperglycemia, and hyperlipidemia were more common with temsirolimus. |
| 2007 | R | Defining the role of mTOR in cancer GUE2007 Comprehensive review arguing mTOR signaling is commonly deregulated in human cancers, laying out the rationale for rapalog trials in oncology. |